Patient-Reported Quality of Life and Treatment Satisfaction in Patients With HR(+)/HER2(-) Advanced/Metastatic Breast Cancer.

Patient-Reported Quality of Life and Treatment Satisfaction in Patients With HR(+)/HER2(-) Advanced/Metastatic Breast Cancer. Clin Ther. 2017 Jul 24;: Authors: Wood R, Mitra D, de Courcy J, Iyer S Abstract PURPOSE: Globally, around 1.67 million new cases of breast cancer are diagnosed each year, with advanced breast cancer (ABC-Stage III) and metastatic breast cancer (MBC-Stage IV) together accounting for up to 22% of incident cases. Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR(+)/HER2(-)) breast cancer comprises 66% of ABC/MBC. Understanding disease-specific health-related quality of life and patient satisfaction with treatments currently available for HR(+)/HER2(-) ABC/MBC in clinical practice is essential for assessing potential unmet need in this patient population. METHODS: Data on treatment patterns in patients with HR(+)/HER2(-) ABC/MBC were collected from oncology practices across the United States and Europe in a cross-sectional study in a clinical practice setting, the Adelphi Real World Advanced Breast Cancer Disease Specific Programme. A subset of patients included in the study completed several self-reported tools, including the Functional Assessment of Cancer Therapy-Breast and the Cancer Therapy Satisfaction Questionnaire. Analyses were conducted using data from the overall cohort and stratified by current treatment, metastatic sites, and number of prior therapy lines. ...
Source: Clinical Therapeutics - Category: Drugs & Pharmacology Authors: Tags: Clin Ther Source Type: research